Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004677410 | SCV005174296 | uncertain significance | not specified | 2024-05-02 | criteria provided, single submitter | clinical testing | The c.53C>T (p.P18L) alteration is located in exon 2 (coding exon 1) of the TRAF3 gene. This alteration results from a C to T substitution at nucleotide position 53, causing the proline (P) at amino acid position 18 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005103494 | SCV005760595 | uncertain significance | Herpes simplex encephalitis, susceptibility to, 3 | 2024-10-28 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 18 of the TRAF3 protein (p.Pro18Leu). This variant is present in population databases (rs145456077, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with TRAF3-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |